Investor Relations

Benchworks Collaborates With Boston Therapeutics to Market sugardown(R)

Download PDF

Launches the Commercialization Phase of sugardown(R) in North America

CHESTERTOWN, MD -- (Marketwired) -- 09/29/14 -- Benchworks is pleased to announce the launch of the commercial phase of sugardown®, a dietary supplement developed by Boston Therapeutics, Inc. (OTCQB: BTHE), that is clinically proven to help control glucose levels when combined with diet and exercise. It is a non-systemic, chewable, complex carbohydrate-based compound, specifically designed to help maintain healthy glucose levels throughout the day. Intended to be taken before meals, sugardown® works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars. This process reduces the amount of glucose available to be absorbed into the bloodstream.

The initial commercialization effort for sugardown® is based on a multichannel strategy including:

  • A multistate partnership with 83bar-Biophysical Prediabetes centers that will introduce sugardown® to thousands of people managing their blood glucose levels

  • The launch of a robust sugardown® e-commerce platform that is optimized to drive significant revenue from the 86 million people managing their blood glucose levels in the United States

  • An active social media strategy designed to foster awareness of sugardown®

  • Updated packaging and sophisticated point-of-sale materials that will enhance consumer adoption for the launch of retail distribution slated to begin in Q1 2015

  • Increase awareness of sugardown® and the importance of maintaining healthy blood sugar levels throughout the day via a professionally executed public relations campaign

Benchworks CEO Thad Bench commented on the initiative, saying, "We are very excited about this partnership. We believe our multichannel marketing approach will generate a lot of excitement and drive sales into the future."

David Platt, Ph.D., CEO of Boston Therapeutics, said, "Implementing this strategy represents the next phase in our commercialization of sugardown®, a product we believe can play a positive role in the lives of many individuals who must watch their blood sugar. Our partnership with Benchworks gives us the leverage we need to maximize the number of customers who will hear about this potentially useful product."

About Benchworks

Benchworks, a comprehensive marketing services firm headquartered in Chestertown, Maryland, was founded in 1991. The company specializes in the design, production, and launch of complete marketing and branding services. Clients include a wide variety of companies in the pharmaceutical, beverage, manufacturing, marine, tourism and education industries in North America and Europe. For more information, visit, or call 800-536-4670.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also developed and currently markets sugardown®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at and

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.


Boston Therapeutics, Inc.
Anthony Squeglia
Chief Financial Officer
Phone: 603-935-9799

Charlotte Zang

860 High Street
Chestertown, MD 21620
phone: 410.810.8862
fax: 410.810.8863

Source: Boston Therapeutics